pavmed inc - PAVM

PAVM

Close Chg Chg %
0.24 -0.02 -8.98%

Open Market

0.21

-0.02 (8.98%)

Volume: 550.47K

Last Updated:

Dec 31, 2025, 11:49 AM EDT

Company Overview: pavmed inc - PAVM

PAVM Key Data

Open

$0.25

Day Range

0.21 - 0.26

52 Week Range

0.21 - 0.90

Market Cap

$7.12M

Shares Outstanding

29.67M

Public Float

25.01M

Beta

1.10

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

$0.37

Yield

0.00%

Dividend

$0.55

EX-DIVIDEND DATE

Jan 11, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

411.86K

 

PAVM Performance

1 Week
 
-18.42%
 
1 Month
 
-36.03%
 
3 Months
 
-45.81%
 
1 Year
 
-62.39%
 
5 Years
 
-99.26%
 

PAVM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About pavmed inc - PAVM

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVM At a Glance

PAVmed, Inc.
360 Madison Avenue
New York, New York 10017
Phone 1-917-813-1828 Revenue 3.00M
Industry Medical Specialties Net Income 39.79M
Sector Health Technology 2024 Sales Growth 22.145%
Fiscal Year-end 12 / 2025 Employees 39
View SEC Filings

PAVM Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 1.265
Price to Sales Ratio 13.68
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.627
Enterprise Value to Sales 23.514
Total Debt to Enterprise Value 0.452

PAVM Efficiency

Revenue/Employee 76,794.872
Income Per Employee 1,020,282.051
Receivables Turnover 166.389
Total Asset Turnover 0.094

PAVM Liquidity

Current Ratio 0.061
Quick Ratio 0.061
Cash Ratio 0.033

PAVM Profitability

Gross Margin -101.603
Operating Margin -1,485.376
Pretax Margin 949.149
Net Margin 1,328.581
Return on Assets 124.778
Return on Equity N/A
Return on Total Capital 135.505
Return on Invested Capital N/A

PAVM Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 108.497
Total Debt to Total Assets 103.914
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 7.652
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Pavmed Inc - PAVM

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
500.00K 377.00K 2.45M 3.00M
Sales Growth
- -24.60% +550.40% +22.15%
Cost of Goods Sold (COGS) incl D&A
811.00K 6.07M 9.35M 6.04M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
226.00K 2.55M 2.93M 1.20M
Depreciation
80.00K 770.00K 911.00K 639.00K
Amortization of Intangibles
146.00K 1.78M 2.02M 559.00K
COGS Growth
+3,426.09% +648.58% +54.04% -35.44%
Gross Income
(311.00K) (5.69M) (6.90M) (3.04M)
Gross Income Growth
-1,252.17% -1,730.87% -21.18% +55.90%
Gross Profit Margin
-62.20% -1,510.34% -281.40% -101.60%
2021 2022 2023 2024 5-year trend
SG&A Expense
54.08M 85.23M 61.90M 41.44M
Research & Development
19.85M 25.55M 14.28M 5.93M
Other SG&A
34.23M 59.69M 47.62M 35.51M
SGA Growth
+131.83% +57.60% -27.38% -33.04%
Other Operating Expense
- - - -
-
Unusual Expense
1.73M 6.71M 10.20M 3.54M
EBIT after Unusual Expense
(56.13M) (97.63M) (78.99M) (48.03M)
Non Operating Income/Expense
- (4.33M) 319.00K 76.50M
Non-Operating Interest Income
- - 505.00K 254.00K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 1.27M 589.00K 45.00K
Interest Expense Growth
- -100.00% -53.69% -92.36%
Gross Interest Expense
- 1.27M 589.00K 45.00K
Interest Capitalized
- - - -
-
Pretax Income
(56.13M) (103.24M) (79.26M) 28.43M
Pretax Income Growth
-56.39% -83.94% +23.22% +135.86%
Pretax Margin
-11,225.20% -27,384.08% -3,232.59% +949.15%
Income Tax
- - - -
-
Income Tax - Current - Domestic
18.94M 13.14M 36.11M 10.69M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(18.94M) (13.14M) (36.11M) (10.69M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(56.13M) (103.24M) (79.26M) 28.43M
Minority Interest Expense
(5.78M) (14.26M) (15.09M) (11.36M)
Net Income
(50.35M) (88.98M) (64.17M) 39.79M
Net Income Growth
-46.89% -76.74% +27.88% +162.00%
Net Margin Growth
-10,069.40% -23,602.92% -2,617.25% +1,328.58%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(50.35M) (88.98M) (64.17M) 39.79M
Preferred Dividends
283.00K 281.00K 2.10M 7.83M
Net Income Available to Common
(50.63M) (89.26M) (66.27M) 31.97M
EPS (Basic)
-9.7974 -15.0317 -9.164 3.3049
EPS (Basic) Growth
+10.36% -53.43% +39.04% +136.06%
Basic Shares Outstanding
5.17M 5.94M 7.23M 9.67M
EPS (Diluted)
-9.7974 -15.0317 -9.164 0.4961
EPS (Diluted) Growth
+10.36% -53.43% +39.04% +105.41%
Diluted Shares Outstanding
5.17M 5.94M 7.23M 65.29M
EBITDA
(54.17M) (88.37M) (65.86M) (43.29M)
EBITDA Growth
-132.20% -63.15% +25.47% +34.27%
EBITDA Margin
-10,833.40% -23,441.11% -2,686.09% -1,445.38%

Snapshot

Average Recommendation BUY Average Target Price 20.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -0.29 Median PE on CY Estimate N/A
Year Ago Earnings 4.114 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Pavmed Inc in the News